ZÜRICH - NLS Pharmaceutics Ltd. (NASDAQ:NLSP), a Swiss biopharmaceutical company, has announced significant findings from its preclinical study of mazindol in a rat model of narcolepsy. The results, presented at the American Society of Clinical Psychopharmacology in Miami, show that mazindol may have a neuroprotective effect on nocturnal activity disrupted by orexin system damage.
In the study, rats with induced narcoleptic-like symptoms received mazindol, which led to a notable improvement in their circadian activity. A dosage of 3 mg/kg of mazindol was particularly effective, restoring and even exceeding the activity levels of a control group without the induced condition. These findings suggest a dose-dependent response, where lower doses did not offer the same therapeutic benefits.
The study also aimed to understand the interaction between mazindol and orexin signaling pathways. Despite no significant change in the number of orexin neurons, the improved activity levels indicate that mazindol's mechanism may involve modulation of orexin receptors or related pathways.
This research supports the potential of mazindol as a treatment for narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden muscle weakness. NLS Pharmaceutics is pursuing further clinical development of the compound, aiming to address the unmet needs of patients with sleep and wakefulness disorders.
NLS Pharmaceutics has a history of developing therapies for central nervous system disorders, including their lead product candidate, Quilience®, which is an extended-release formulation of mazindol. Quilience® has received Orphan Drug Designations in the U.S. and Europe for narcolepsy treatment and has shown promise in early clinical trials.
The company's recent study contributes to the understanding of narcolepsy's underlying mechanisms and the potential role of mazindol in managing the disorder. The findings are available on the company's website, and further information can be accessed from the abstract presented at the ASCP conference.
The information in this article is based on a press release statement from NLS Pharmaceutics.
InvestingPro Insights
Amid the scientific advancements reported by NLS Pharmaceutics Ltd. (NASDAQ:NLSP) in the treatment of narcolepsy, the company's financial health as reflected by recent market data presents a mixed picture. From an InvestingPro standpoint, NLSP has demonstrated a significant return over the last month, with a 27.29% increase in price total return. This uptick might reflect investor optimism following the promising results of their preclinical study.
However, it's important to note that NLSP has also experienced a substantial decline over the last year, with an 83.43% drop in the 1-year price total return, indicating that the company's journey has been volatile for investors. Additionally, the company's market capitalization stands at a modest 8.2 million USD, which could suggest a smaller, potentially riskier investment in the biopharmaceutical sector.
From an operational perspective, InvestingPro Tips highlight that NLSP operates with a moderate level of debt and has not been profitable over the last twelve months. The company's P/E Ratio (Adjusted) for the last twelve months as of Q4 2023 stands at -0.67, reinforcing the fact that profitability remains a challenge. Moreover, short-term obligations exceed its liquid assets, which could pose liquidity risks for the company.
For investors interested in a deeper analysis, there are additional InvestingPro Tips available that could provide further insights into NLSP's financial performance and potential investment risks. To explore these tips and enhance your investment strategy, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.